Search details
1.
FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Oncologist
; 26(10): 879-886, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34132444
2.
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
Oncologist
; 22(11): 1347-1353, 2017 11.
Article
in English
| MEDLINE | ID: mdl-28904172
3.
Immunotherapy Combinations in Multiple Myeloma - Known Unknowns.
N Engl J Med
; 379(19): 1791-1795, 2018 Nov 08.
Article
in English
| MEDLINE | ID: mdl-30403935
4.
Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation.
Biol Blood Marrow Transplant
; 20(7): 969-78, 2014 Jul.
Article
in English
| MEDLINE | ID: mdl-24657447
5.
FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma.
Clin Cancer Res
; 30(1): 17-22, 2024 01 05.
Article
in English
| MEDLINE | ID: mdl-37624619
6.
Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective.
Clin Cancer Res
; 29(15): 2748-2752, 2023 08 01.
Article
in English
| MEDLINE | ID: mdl-36892497
7.
The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990-2018.
Cancer Epidemiol Biomarkers Prev
; 32(6): 744-747, 2023 06 01.
Article
in English
| MEDLINE | ID: mdl-37012203
8.
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.
Cancer Discov
; 13(12): 2515-2524, 2023 12 12.
Article
in English
| MEDLINE | ID: mdl-38084090
9.
The rising incidence of intentional ingestion of ethanol-containing hand sanitizers.
Crit Care Med
; 40(1): 290-4, 2012 Jan.
Article
in English
| MEDLINE | ID: mdl-21926580
10.
Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data.
Blood Cancer J
; 12(4): 65, 2022 04 19.
Article
in English
| MEDLINE | ID: mdl-35440047
11.
FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.
Clin Cancer Res
; 28(21): 4629-4633, 2022 11 01.
Article
in English
| MEDLINE | ID: mdl-35736811
12.
Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025.
Clin Cancer Res
; 28(1): 23-26, 2022 01 01.
Article
in English
| MEDLINE | ID: mdl-34315721
13.
Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples.
Clin Cancer Res
; 27(21): 5753-5756, 2021 11 01.
Article
in English
| MEDLINE | ID: mdl-34117032
14.
The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology.
Clin Cancer Res
; 27(19): 5161-5167, 2021 10 01.
Article
in English
| MEDLINE | ID: mdl-33910935
15.
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
Clin Cancer Res
; 27(19): 5195-5212, 2021 10 01.
Article
in English
| MEDLINE | ID: mdl-34321279
16.
FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.
Clin Cancer Res
; 23(22): 6759-6763, 2017 Nov 15.
Article
in English
| MEDLINE | ID: mdl-28249893
17.
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Clin Cancer Res
; 23(15): 3980-3993, 2017 Aug 01.
Article
in English
| MEDLINE | ID: mdl-28428191
18.
Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.
Cytometry B Clin Cytom
; 90(1): 73-80, 2016 Jan.
Article
in English
| MEDLINE | ID: mdl-26108351
19.
Minimal Residual Disease as a Potential Surrogate End Point-Lingering Questions.
JAMA Oncol
; 3(1): 18-20, 2017 Jan 01.
Article
in English
| MEDLINE | ID: mdl-27632052
Results
1 -
19
de 19
1
Next >
>>